# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and mai...
EF Hutton analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $14 price target.
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys...
EF Hutton analyst Jason Kolbert initiates coverage on CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy rating and announce...
Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim ...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and mai...